R. Scott Shean

scott.shean@lw.com

+1.714.755.8152

Profile

Scott Shean serves as primary outside counsel to several public and private companies in various industries, including healthcare, technology, and real estate. His practice focuses on mergers and acquisitions, corporate governance, and capital markets, and he has led the firm’s representation on numerous high profile and complex transactions. Scott is former Corporate Department Chair of the Orange County office and former Global Co-Chair of Latham’s Healthcare and Life Sciences Practice. He formerly served a seven-year term as the Managing Partner of the Orange County office.

Scott has extensive experience in mergers and acquisitions and capital markets transactions, representing both companies and investment banks.

Experience

Scott's representative transactions include:

Verona Pharma in its US$10 billion sale to Merck
Merus N.V. in its US$8 billion sale to Genmab
scPharma in its merger with MannKind
atai Life Sciences in its merger with Beckley Psytech
Obagi in its US$1.2 billion business combination with Waldencast and Milk Makeup
Zogenix in its US$2 billion sale to UCB
ChemoCentryx in its US$3.7 billion sale to Amgen
Sobi in its $1.7 billion acquisition of CTI BioPharma
OmniAb in its US$850 million merger with Avista Public Acquisition Corp.
Momenta Pharmaceuticals in its US$6.5 billion sale to J&J
Ra Pharma in its US$2.5 billion sale to UCB
Ligand Pharmaceuticals in its US$500 million acquisition of Pfenex
Allergan (formerly Actavis/ Watson) in its:
- US$40.5 billion sale of its Global Generic Pharmaceuticals Business to Teva
- US$25 billion acquisition of Forest Laboratories
- £306 million acquisition of Auden Mckenzie Holdings Limited
- US$8.5 billion acquisition of Warner Chilcott
- Watson Pharmaceuticals in its US$5.65 billion acquisition of Actavis Group and related financings
- Watson Pharmaceuticals in its US$1.8 billion acquisition of Arrow Group
- Watson Pharmaceuticals in its US$2 billion acquisition of Andrx Corporation
Ignyta, Inc. in its US$1.7 billion sale to Roche
Akebia in its merger with Keryx
Sobi in its US$1.5 billion acquisition of RSV Products from AstraZeneca
5.11 Tactical in its US$400 million sale to Compass Diversified Holdings
Receptos in its US$7.2 billion sale to Celgene
Questcor Pharmaceuticals in its US$5.6 billion sale to Mallinckrodt plc
Ariosa Diagnostics in its sale to Roche
Avanir Pharmaceuticals in its US$3.5 billion sale to Otsuka Pharmaceutical
J.P. Morgan as financial advisor to Thermo Fisher in its US$13.6 billion acquisition of Life Technologies
Medicis Pharmaceutical in the US$2.6 billion sale to Valeant Pharmaceuticals
Goldman, Sachs & Co. in the US$7 billion acquisition of Amylin Pharmaceuticals by Bristol-Myers Squibb
Quest Software in its US$2.4 billion sale to Dell
Complete Production Services in its US$6.2 billion merger with Superior Energy Services
Clarient in its US$600 million sale to General Electric
Visiogen, Inc. in its US$400 million sale to Abbott Laboratories
HCP, Inc. in its US$3 billion acquisition of Slough Estates USA
ICOS Corporation in its US$2.1 billion sale to Eli Lilly
FileNet Corporation in its US$1.6 billion sale to IBM
Varco International, Inc. in its US$5 billion merger with National Oilwell
Harrah’s Entertainment, Inc. in its US$10.3 billion acquisition of Caesars Entertainment
Pan Pacific Retail Properties, Inc. in its multi-billion dollar acquisitions of Western Properties Trust and Center Trust, Inc.
Paul Frank Industries in its sale to Saban Capital
Automotive.com in its sale to Primedia, Inc.